Lineage Cell Therapeutics, Inc. Common Stock (LCTX)

LCTX stock results show that Lineage Cell Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

LCTX stock results show that Lineage Cell Therapeutics met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

LCTX stock results show that Lineage Cell Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.

The Dow Jones index closed higher by around 25 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

While penny stocks to buy represent a terribly risky venture, it’s possible that maybe one of these ideas could skyrocket.

Here are the best longevity stocks to consider. Each stock listed comes with their unique reasons to buy them.

Lineage Cell Therapeutics Inc (NYSE: LCTX) has initiated certain development activities to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line under the company’s exclusive option and license agreement with Eterna Therapeutics Inc (NASDAQ:

Gainers

Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.